Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 62-76 http://medscipublisher.com/index.php/cge 72 expression, and "acquired genetic alterations" is also a complex task, and there is still a lack of unified methods and analytical tools (Jammula et al., 2020). 10.2 Technological progress and its potential Despite these difficulties, the development of technology has brought new hope to EAC research. Next-generation sequencing (NGS) technology enables us to discover many somatic mutations and key genes, greatly changing our understanding of the EAC gene situation (Frankell et al., 2018). If sequencing methods that are cheaper and have higher detection efficiency can be developed in the future, larger-scale and more comprehensive studies can be carried out, allowing us to have a deeper understanding of the molecular mechanism of EAC (Contino et al., 2017). Furthermore, the advancements in single-cell sequencing and spatial transcriptomics technologies have helped us understand the differences within tumors and the interactions between tumors and their surrounding environment. These factors can affect the development of EAC and drug resistance (Murugaesu et al., 2015). Nowadays, it has become more feasible to conduct a comprehensive analysis of data from multiple aspects such as genes, gene expression and "acquired genetic alterations", which enables us to have a more comprehensive understanding of this disease (Jammula et al., 2020). In addition, by using organoid models and patient-derived transplantation models, more realistic experimental models can be established to test targeted therapeutic drugs and study the mechanism of drug resistance (Frankell et al., 2018; Jammula et al., 2020). 10.3 Future research focus of EAC genomics In order to solve the existing problems and better utilize the benefits brought by technology, the following points should be particularly noted in future research on esophageal adenocarcinoma (EAC) genes. First of all, it is necessary to organize many people to conduct research together in many places, including different people and different periods of diseases, so as to have a more comprehensive understanding of the genetic differences of EAC (Stachler et al., 2018). These studies also need to look at various data together so as to fully demonstrate the characteristics of EAC at the molecular level (Jammula et al., 2020). Secondly, it is necessary to thoroughly study why genes are always unstable and what role this instability plays in the aggravation of EAC and the ineffectiveness of drugs. Identifying the main causes of genetic instability may help us find new treatment methods (Kumar et al., 2021). In addition, it is necessary to find and confirm some reliable methods to judge the condition, predict the outcome and see if the treatment is effective. This includes seeing whether non-surgical examination methods such as tumor DNA in the blood (ctDNA) are really effective (Slaby et al., 2015; Stachler et al., 2018). Finally, the focus of future research should be on how to truly apply the findings of genetic research to treating diseases and design targeted treatments and personalized plans. This requires close cooperation among researchers, doctors and pharmaceutical companies to enable new research results to be applied to patients more quickly and effectively (Nagaraja et al., 2019). 11 Concluding Remarks Esophageal adenocarcinoma (EAC) is a kind of cancer with a high degree of malignancy and poor treatment effect. In Western countries, the number of people suffering from it is increasing. By studying genes, scientists have clarified how EAC occurs and identified genes and pathways such as TP53, CDKN2A, KRAS and ERBB2 that play a key role in the progression of the disease. Gene mutations, instability, and changes in the way DNA methylation occurs-these gene-level changes are all very important in the occurrence and deterioration of EAC. In addition, studies on gene expression have found that there are significant individual differences in EAC, and different types of patients respond differently to chemotherapy, which makes the treatment of this disease more difficult. The achievements of genetic research have brought about significant changes in the treatment and management of esophageal cancer. The discovery of specific genetic errors and intracellular activity processes has brought new approaches to the development of precision drugs. For example, drugs specifically targeting TP53 and CDK4/CDK6 gene problems may help patients recover better. Analyzing the information of the gene itself and the changes of the gene in life together can make people better understand how EAC occurs. Some new physical signals have also been identified, which can help detect diseases earlier and formulate more useful treatment plans.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==